Literature DB >> 12947024

Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis.

Sylvain Marchand-Adam1, Joëlle Marchal, Murielle Cohen, Paul Soler, Bénédicte Gerard, Yves Castier, Guy Lesèche, Dominique Valeyre, Hervé Mal, Michel Aubier, Monique Dehoux, Bruno Crestani.   

Abstract

Hepatocyte growth factor (HGF) is a growth factor that protects alveolar epithelial cells from pulmonary fibrosis in various animal models. We compared in vitro HGF production by human lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF, n = 8) and from control subjects (n = 6). Basal HGF secretion by IPF fibroblasts was decreased by 50% when compared with control fibroblasts (p < 0.05). HGF was secreted mainly in the cleaved mature form, both in IPF and control fibroblasts. HGF messenger RNA levels were reduced in IPF fibroblasts. Prostaglandin (PG) E2 secretion by IPF fibroblasts was low when compared with control subjects (p < 0.05). After the addition of PGE2 (10-6 M) or dibutyryl cyclic AMP (10-3 M), HGF secretion by IPF fibroblasts reached the level of control subjects. Inhibition of PGE2 synthesis with indomethacin reduced HGF secretion by control fibroblasts but had no effect on IPF fibroblasts. HGF secretion by control fibroblasts was also slightly inhibited by transforming growth factor (TGF)-beta1 and stimulated by anti-TGF-beta antibody, whereas both agents had no effect on IPF fibroblasts. Our results demonstrate a defect in HGF production by IPF fibroblasts that seems secondary to a defect in PGE2 secretion.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12947024     DOI: 10.1164/rccm.200212-1514OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  24 in total

1.  Macrophage-stimulating protein differently affects human alveolar macrophages from smoker and non-smoker patients: evaluation of respiratory burst, cytokine release and NF-kappaB pathway.

Authors:  Gabriele Gunella; Claudio Bardelli; Angela Amoruso; Ilario Viano; Piero Balbo; Sandra Brunelleschi
Journal:  Br J Pharmacol       Date:  2006-04-24       Impact factor: 8.739

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

3.  Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis.

Authors:  Katri Koli; Marjukka Myllärniemi; Kirsi Vuorinen; Kaisa Salmenkivi; Merja J Ryynänen; Vuokko L Kinnula; Jorma Keski-Oja
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

4.  Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis.

Authors:  Franco Conforti; Robert Ridley; Christopher Brereton; Aiman Alzetani; Benjamin Johnson; Ben G Marshall; Sophie V Fletcher; Christian H Ottensmeier; Luca Richeldi; Paul Skipp; Yihua Wang; Mark G Jones; Donna E Davies
Journal:  Cell Death Discov       Date:  2020-06-30

5.  Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon.

Authors:  Ying Xia; Yu-Feng Xia; Qi Lv; Meng-Fan Yue; Si-Miao Qiao; Yan Yang; Zhi-Feng Wei; Yue Dai
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

Review 6.  Epithelial-mesenchymal interactions in pulmonary fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Semin Respir Crit Care Med       Date:  2006-12       Impact factor: 3.119

7.  NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGFbeta1-induced fibroblast differentiation into myofibroblasts.

Authors:  Nadia Amara; Delphine Goven; Fabienne Prost; Rachel Muloway; Bruno Crestani; Jorge Boczkowski
Journal:  Thorax       Date:  2010-08       Impact factor: 9.139

8.  Epithelial-mesenchymal crosstalk influences cellular behavior in a 3D alveolus-fibroblast model system.

Authors:  Katherine J R Lewis; Jessica K Hall; Emi A Kiyotake; Tova Christensen; Vivek Balasubramaniam; Kristi S Anseth
Journal:  Biomaterials       Date:  2017-11-15       Impact factor: 12.479

Review 9.  Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?

Authors:  Steven K Huang; Marc Peters-Golden
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 10.  New mechanisms of pulmonary fibrosis.

Authors:  Robert M Strieter; Borna Mehrad
Journal:  Chest       Date:  2009-11       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.